Vertex (VRTX) Slumps on VX-809 Data Presentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Analyst Says Vertex (VRTX) Drug Data Shows "At Least Moderate Impact"
October 12, 2012 8:29 AM EDTVertex Pharmaceuticals (Nasdaq: VRTX) presented additional data from cohort 2 of the Phase 2 VX-809 (lumacaftor/ivacaftor) trial in F508del cystic fibrosis patients at the NACFC meeting yesterday.
Commenting on the data, analyst Alan Carr of Needham and Company said "Although interpretation... More
